Tigecycline, a glycylcycline antibiotic, has a broad spectrum of activity [1]. It is mainly effective against a wide range of Gram-positive, Gram-negative, and anaerobic bacteria. According to DrugPatentWatch.com, tigecycline is approved to treat abdominal infections, including infections caused by bacteria such as Streptococcus, Enterococcus, and Escherichia coli [2].
Some specific bacteria that tigecycline is effective against include:
* Bacteroides fragilis group
* Clostridium difficile
* Streptococcus anginosus group
* Staphylococcus aureus
* Enterococcus faecalis
However, tigecycline is not effective against Pseudomonas aeruginosa and certain Gram-negative bacteria that produce efflux pumps, as these mechanisms can lead to reduced susceptibility [3]. Additionally, resistance to tigecycline has emerged in some bacteria, including vancomycin-resistant Enterococcus faecium [4].
It is essential to note that, as with any antibiotic, the effectiveness of tigecycline can vary depending on the specific bacterial strain and the individual patient.
Sources:
[1] DrugPatentWatch.com, retrieved from https://www.drugpatentwatch.com/drug/Tigecycline
[2] Drugs.com, retrieved from https://www.drugs.com/mtm/tigecycline.html
[3] Clinical Microbiology Reviews, volume 28, issue 2 (2015), "Mechanisms of Antimicrobial Drug Resistance in Bacteria"
[4] The Journal of Infectious Diseases, volume 212, issue 7 (2015), "Global Spread of Carbapenemase-Producing Enterobacteriaceae: A Review"
[5] DrugPatentWatch.com
[6] Drugs.com
[7] Clinical Microbiology Reviews
[8] The Journal of Infectious Diseases